Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

research
Tuesday, September 4, 2018

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, GWPCARE3 Study Group. N Engl J Med, May 17, 2018; 378:1888-1897.

The following study published in the New England Journal of Medicine presented results from a study of cannabidiol in people with Lennox-Gastaut syndrome (LGS).

Purpose

Description of Study

  • People with LGS between the ages of 2 and 55 years old were randomized to different groups. Two doses of CBD were tested. One group was given CBD 20 mg/kg, one group was given CBD 10 mg/kg daily, and one group was given a placebo.
  • This study was done at 30 epilepsy centers.
  • The scientists looked at the change in number of atonic or drop seizures in people taking the CBD as compared to those taking the placebo.

Summary of Study Findings

  • Both doses of CBD were associated with a decrease in the number of drop seizures as compared to placebo.
  • The most common side events were sleepiness, diarrhea, and decreased appetite. These were more common in people taking 20 mg CBD as compared to the 10 mg CBD or placebo.

What does this mean?

Authored by: Sloka Iyengar PhD | Basic Science Editor on 9/2018
Reviewed by: Patty Osborne Shafer RN MN | Associate Editor and Senior Director on 9/2018

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline